Cytokine genetic adjuvant facilitates prophylactic intravascular DNA vaccine against acute and latent herpes simplex virus infection in mice.
Intravascular plasmid DNA (pDNA) vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) effectively induces prophylactic immunity against lethal HSV-1 infection in mice. We investigated whether the vaccine potency is further improved by coadministration of cytokine genes together with a low dose of genetic vaccine. pDNA encoding IL-12, IL-15, IL-18 or IL-21 was capable of elevating survival rates of HSV-1-infected mice when coinjected with 1 microg of gB pDNA, while IL-10 gene delivery failed to affect the effectiveness of the genetic immunization. Although only 17% of mice survived acute HSV infection after the gB pDNA vaccination at a dose of 1 microg, all mice coadministered with 1 microg each of gB and IL-12 pDNAs not only survived the acute infection but also escaped latent infection. In these animals, the neutralizing antibody against HSV-1 was abundantly produced, and CTL activity against the gB antigen was augmented. Coadministration of the gB and IL-12 genes also elevated the serum level of interferon-gamma. Adaptive transfer experiments indicated that soluble factors contributed to preventive immunity, while cell components alone were not capable of protecting mice from fatal viral infection. These results strongly suggest potential usefulness of Th1 cytokine genes as effective molecular adjuvants that facilitate specific humoral as well as cellular immune responses elicited by intravascular molecular vaccination.
Cui
F-D
FD
Department of Microbiology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Asada
H
H
Jin
M-L
ML
Kishida
T
T
Shin-Ya
M
M
Nakaya
T
T
Kita
M
M
Ishii
M
M
Iwai
M
M
Okanoue
T
T
Imanishi
J
J
Mazda
O
O
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D016207:Cytokines / Q000235:genetics* / Q000276:immunology; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006561:Herpes Simplex / Q000276:immunology / Q000628:therapy*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage*; D016233:Immunotherapy, Active / Q000379:methods*; D007275:Injections, Intravenous; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology; D019409:Interleukin-15 / Q000235:genetics / Q000276:immunology; D020382:Interleukin-18 / Q000235:genetics / Q000276:immunology; D007378:Interleukins / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage*; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology; D017735:Virus Latency; D000098546:Interleukin-21
D000276:Adjuvants, Immunologic; D016207:Cytokines; D022283:Herpesvirus Vaccines; D019409:Interleukin-15; D020382:Interleukin-18; D007378:Interleukins; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; D018664:Interleukin-12; D000098546:Interleukin-21